Absci (ABSI) Q2 2026 Earnings Call Transcript
Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.
How this was made
The 30-second read
Why it matters
Earnings miss and cash infusion could drive short-term volatility; long-term pipeline progress remains key.
Market read
The earnings release provides fresh financial data and financing details that may affect ABSI's stock and broader biotech sentiment.
What to watch
Potential regulatory milestones for ABS-201 could unlock significant upside beyond current earnings focus.
Background
Absci Corp is a biotech company developing AI-driven therapeutics, recently raising capital and reporting Q2 results.
Ticker impact
Q2 2026 earnings call disclosed revenue of $0.3M, net loss of $33.2M, and a $93.6M financing round including $40M from Eli Lilly.
Potential near-term downside pressure with upside upside if financing is viewed positively.
Loss widened YoY and revenue halved, but cash position improved; market reaction will hinge on financing perception.
Market effects
Highlights ongoing investment in AI-driven drug discovery within biotech sector.
US biotech investors may reassess cash burn vs financing trends.
Eli Lilly's strategic investment signals larger pharma interest in AI platforms.
Counterpoint
Financing may be seen as a vote of confidence, supporting a longer-term bullish case.
Key entities
- CompanyAbsci Corp
Biotech firm developing AI-driven drug candidates.
- Strategic InvestorEli Lilly
Provided $40M strategic investment for ABS-201 program.
